Related Experiment Video

Updated: Apr 20, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.6K

[Mechanisms of resistance to anti-BRAF treatments]

J Charles1, C Martel2, F de Fraipont3

  • 1Centre de recherche Inserm/UJF U823, institut Albert-Bonniot, BP 170, 38042 Grenoble cedex 9, France; Dermatologie, CHU de Grenoble, CS 10217, 38043 Grenoble cedex 9, France.

Annales De Dermatologie Et De Venereologie
|December 3, 2014
PubMed
Abstract

Insights

Targeted BRAF inhibitors offer initial melanoma treatment benefits but resistance develops quickly. Understanding these resistance mechanisms is key to improving long-term patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • BRAF V600 mutation-positive melanoma patients show rapid response to targeted BRAF inhibitors.
  • Treatment benefits include improved progression-free and overall survival.
  • However, resistance to these therapies typically emerges within six months, limiting long-term efficacy.

Purpose of the Study:

  • To elucidate resistance mechanisms against targeted anti-BRAF therapies in melanoma.
  • To review BRAF signaling pathways and clinical trial data.
  • To identify strategies for overcoming treatment resistance and improving patient response duration.

Main Methods:

  • Literature review of articles published before January 31, 2014.
  • Keywords used: resistance, BRAF, melanoma, targeted therapy, vemurafenib, dabrafenib.
  • Database searched: Medline/Pubmed.

Main Results:

  • BRAF inhibitors induce initial clinical responses in melanoma.
  • Resistance mechanisms are a significant factor limiting sustained therapeutic effects.
  • Understanding these mechanisms is crucial for future treatment development.

Conclusions:

  • Enhanced understanding of resistance mechanisms is vital for developing novel therapeutic strategies.
  • Overcoming resistance can lead to more significant and sustained response rates in melanoma patients.
  • Further research into resistance pathways will improve targeted therapy efficacy.
Keywords:
BRAFDabrafenibMelanomaMutationMélanomeResistanceRésistanceTargeted therapyThérapie cibléeVemurafenib

More Related Videos

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells06:44

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells

Published on: March 1, 2024

1.9K
Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma08:18

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

3.5K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.8K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

4.4K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.6K